Williams 2013.

Methods	Quasi‐experimental historically controlled study ‐ with control group (CG) and intervention group (IG)
Participants	Adult cancer patients that had started chemo‐ and/or radiotherapy Country: USA Age: IG: mean 58.24 years (9.14 SD), CG: mean 62.33 years (10.49 SD) Sex: IG: 55.2% female; CG: 63.6% female Inclusion criteria at least 1 day of treatment (radio‐ or chemotherapy, or both) not participating in an ongoing clinical trial no diagnosed psychopathology ≥ 18 years spoke/read English Eastern Cooperative Oncology Group score ≤ 3 or Karnofsky score ≥ 60 Exclusion criteria: / N recruited: N = 128, IG: n = 64, CG: n = 64 N in analysis: N = 113; IG: n = 58; CG: n = 55
Interventions	Content of screen:PHYSICAL AND PSYCHOLOGICAL SYMPTOMS: tool= TRSC: PROM; 25 symptoms (taste change, loss of appetite, nausea, vomiting, weight loss, sore mouth, cough, sore throat, difficulty swallowing, jaw pain, shortness of breath, numbness of fingers/toes, feeling sluggish, depression, difficulty concentrating, fever, bruising, bleeding, hair loss, skin changes, soreness in vein where chemotherapy was given, difficulty sleeping, pain, decreased interest in sexual activity, constipation) rated using a 5‐point scale; 0 (not present) to 4 (very severe); scores indicate occurrence and severity Screenings interventionist: No interventionist for screening act, self‐completion of screening tool. Intervention procedure:Solitary SI: participants completed TRSC prior to clinical consultation. Clinicians received results of the completed screening intervention form prior to consultation, however they received no training on how to use the form Conditions for implementation a system/person is needed to deliver and collect questionnaires and to control data management training of clinic staff in the use of the study instruments and the importance of complete and consistent follow‐up to accrue at least 5 complete sets of instruments from each participant, and advised that on the participant's completion of the form the provider was to be given a copy Comparative condition: CG: usual care: chemo‐ and radiotherapy, with a wide range of supportive therapies available. Documentation and management of symptoms is done by clinicians and nurses using the standard clinic interview and medical record Length of follow‐up: 4 months
Outcomes	Primary outcomes HRQoL (HRQoL‐LASA) Secondary outcomes number of symptoms identified and managed Outcome time points: variable: RT patients completed instruments once weekly on the same day each week. CT patients completed instruments on the day of provider evaluation prior to receiving CT on day 1 of each cycle. The number of RT and CT cycles varied, depending on treatment protocol
Notes	For bias judgement on NRCTs, see Table 3; Table 4; Table 9